Identification of a Novel EML4-ALK, BCL11A-ALK Double-Fusion Variant in Lung Adenocarcinoma Using Next-Generation Sequencing and Response to Crizotinib

J Thorac Oncol. 2019 Jun;14(6):e115-e117. doi: 10.1016/j.jtho.2019.01.032.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adenocarcinoma of Lung / drug therapy*
  • Adenocarcinoma of Lung / genetics*
  • Adenocarcinoma of Lung / pathology
  • Adult
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use*
  • Crizotinib / pharmacology
  • Crizotinib / therapeutic use*
  • High-Throughput Nucleotide Sequencing / methods*
  • Humans
  • Male
  • Nuclear Proteins / genetics*
  • Oncogene Proteins, Fusion / genetics*
  • Repressor Proteins / genetics*

Substances

  • Antineoplastic Agents
  • BCL11A protein, human
  • EML4-ALK fusion protein, human
  • Nuclear Proteins
  • Oncogene Proteins, Fusion
  • Repressor Proteins
  • Crizotinib